Vancouver, Canada – August 20, 2025 – THC BioMed (CSE: THC) (OTCQB: THCBF) THC BioMed Intl Ltd. (“THC BioMed”) or (the “Company”) is pleased to announce that it has entered into an agreement to export at least 800 kilograms of cannabis over the next two years to a prominent distributor (the “Distributor”) of pharmaceutical cannabis products in Germany and other parts of Europe.
This agreement marks a significant milestone in THC BioMed’s expansion into the European market.
Under the terms of the agreement:
- THC BioMed Ltd. will supply stabilized dried cannabis flowers cultivated under GACP-Plus standards to the Distributor for distribution in Germany and the European Economic Area (EEA).
- The agreement includes two exclusive strains and the Distributor will have exclusive distribution rights for these strains in Germany.
- The Distributor commits to a minimum annual order quantity of 400kg per year, split across shipments and strains and based on mutually agreed forecasts.
Key Features of the Agreement:
- Quality Assurance: THC BioMed will provide a Certificate of Analysis (CoA) for each shipment, ensuring compliance with stringent quality standards outlined in the agreement.
- Delivery Terms: Shipments will be delivered DAP (Incoterms 2020) to a GMP-licensed facility in the EEA, with THC BioMed bearing all risks and costs of transport.
- Payment: Payments from the Distributor will be split into two installments: 50% pre-shipment and 50% post-inspection.
- Defect and Delay Management: the Distributor retains the right to claim credits or cancel orders in case of delays or product defects, ensuring reliability and accountability.
- Regulatory Compliance: Both parties will ensure adherence to all necessary licenses, permits, and regulatory requirements for the import and export of cannabis products.
John Miller, CEO of THC BioMed Ltd., stated: “We are thrilled to partner with this distributor to bring our cannabis products to the European market. This agreement underscores our commitment to quality, reliability, and growth of the business.”
The agreement has a two-year term and is set to automatically renew for six-month periods after that, unless terminated by either party with prior notice.
About THC Biomed:
THC Biomed is a leading cannabis company dedicated to producing high-quality, diverse cannabis products. With a focus on innovation and consumer satisfaction, THC Biomed strives to meet the evolving needs of cannabis enthusiasts through continuous research, development, and product excellence.
For more information, contact:
John Miller
CEO THC BioMed Intl Ltd.
T: 1-844-THCMEDS
E: info@thcbiomed.com
Forward-Looking Information:
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of THC BioMed. Forward-looking information is based on certain key expectations and assumptions made by the management of THC BioMed. In some cases, you can identify forward-looking statements using words such as “will,” “may,” “would,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “could” and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Forward-looking statements in this press release include that the Company will export the quantity of cannabis as described. Although THC BioMed believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because THC BioMed can give no assurance that they will prove to be correct. THC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.